Toxic epidermal necrolysis (TEN) is a rare, life-threatening skin reaction, usually caused by a medication. It's a severe form of Stevens-Johnson syndrome (SJS). In people with SJS, TEN is diagnosed when more than 30% of the skin surface is affected and the moist linings of the body (mucous membranes) have extensive damage.

TEN is a life-threatening condition that affects people of all ages. TEN is usually treated in a hospital. While the skin heals, supportive care includes controlling pain, caring for wounds and making sure you're getting enough fluids. Recovery can take weeks to months.

If your condition was caused by a medication, you'll need to permanently avoid that drug and those related to it.


Toxic epidermal necrolysis signs and symptoms include:

  • Widespread skin pain
  • A spreading rash covering more than 30% of the body
  • Blisters and large areas of peeling skin
  • Sores, swelling and crusting on the mucous membranes, including the mouth, eyes and vagina

When to see a doctor

Early treatment is key for people with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). If you have symptoms, seek immediate medical attention. You'll likely need care from a skin specialist (dermatologist) and other experts in a hospital.


SJS/TEN is usually caused by a skin reaction to medicine. The symptoms are likely to start showing up one to four weeks after you start taking a new drug.

The most common drug triggers of SJS/TEN include antibiotics, epilepsy drugs, sulfa drugs and allopurinol (Aloprim, Zyloprim).

Risk factors

Factors that increase your risk of SJS/TEN include:

  • HIV infection. Among people with HIV, the incidence of SJS/TEN is about 100 times greater than that among the general population.
  • A weakened immune system. The immune system can be affected by an organ transplant, HIV/AIDS and autoimmune diseases.
  • Cancer. People with cancer, especially blood cancers (hematologic malignancies), are at increased risk of SJS/TEN.
  • A history of SJS/TEN. If you've had a medication-related form of this condition, you are at risk of a recurrence if you use that drug again.
  • A family history of SJS/TEN. If a first-degree relative, such as a parent or sibling, has had SJS/TEN, you may be more susceptible to developing it too.
  • Genetic factors. Having certain genetic variations puts you at increased risk of SJS/TEN, especially if you're also taking drugs for seizures, gout or mental illness.


People at highest risk of TEN complications are those over age 70 and those who have liver cirrhosis or spreading (metastatic) cancer. Complications of TEN include:

  • Blood infection (sepsis). Sepsis occurs when bacteria from an infection enter your bloodstream and spread throughout your body. Sepsis is a rapidly progressing, life-threatening condition that can cause shock and organ failure.
  • Lung involvement. This can cause coughing, difficulty breathing and, with severe disease, acute respiratory failure.
  • Visual impairment. TEN can cause eye problems, such as dry eye, ingrown eyelashes, corneal scarring and, rarely, blindness.
  • Permanent skin damage. After recovering from TEN, your skin may have bumps, scars and discoloration. Lasting skin problems might cause your hair to fall out, and your fingernails and toenails might not grow normally.
  • Vaginal sores. In women, TEN can cause sores in the tissues lining the vagina, leading to pain or, if left untreated, vaginal fusion.
  • Emotional distress. This condition causes distress and can have long-term psychological impact.


To prevent another episode of TEN, learn whether it was caused by a medicine. If so, never take that medicine or anything similar again. A recurrence could be worse and life-threatening. Also tell any future health care providers about your history of TEN, and wear a medic alert bracelet or necklace with information about your condition. Or carry an allergy passport.

Aug. 29, 2020
  1. AskMayoExpert. Drug eruption. Mayo Clinic; 2020.
  2. AskMayoExpert. Nonimmunoglobulin e-mediated (non-IgE) drug sensitivity. Mayo Clinic; 2019.
  3. Seminario-Vidal L., et al. Society of dermatology hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. Journal of the American Academy of Dermatology. 2020; doi.org/10.1016/j.jaad.2020.02.066.
  4. Micheletti RG, et al. Stevens-Johnson syndrome/toxic epidermal necrolysis: A multicenter retrospective study of 377 adult patients from the United States. Journal of Investigative Dermatology. 2018; doi.org/10.1016/j.jid.2018.04.027.
  5. Whitney AH. Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae. https://www.uptodate.com/contents/search. Accessed July 23, 2020.
  6. Whitney AH. Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis. https://www.uptodate.com/contents/search. Accessed July 23, 2020.
  7. O'Reilly P., et al. the psychological impact of Stevens-Johnson syndrome and toxic epidermal necrolysis on patients' lives: A critically appraised topic. British Journal of Dermatology. 2019; doi 10.1111/bjd.18746.
  8. Kellerman RD, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis. In: Conn's Current Therapy 2020. Elsevier; 2020. https://www.clinicalkey.com. Accessed July 27, 2020.